Week in Review: China Life Science Goes International for Deals

Hutchison China MediTech will contribute $50 million to its partnership with AstraZeneca to accelerate global clinical development of savolitinib, a c-MET inhibitor; Ambrx, a San Diego-China biopharma, closed a $45 million financing to underwrite a Phase I trial of a HER2-positive breast cancer treatment; Ornim of Israel raised $20 million from China investors for its non-invasive perfusion measurement medical device; Shangdong Luoxin Pharma in-licensed China rights to a lung cancer drug candidate from South Korea's Yuhan in a $120 million deal; San Diego's Sorrento will form an immuno-oncology joint venture with CHA Biotech of South Korea; Ligand Pharma of San Diego formed a new company to develop three preclinical Ligand programs in China; Ossen Innovation, a Shanghai company, plans to transform itself into a glucose monitoring medical device maker via an acquisition; Chengdu Olymvax Biopharma in-licensed greater China rights to a novel Group A Streptococcus (GAS) vaccine developed by Australia's Griffith University; and ViroMed of South Korea obtained Investigational New Drug approval for its lead gene therapy drug candidate in Korea. More details.... Stock Symbols: (AIM: HCM; NSDQ: HCM) (NYSE: AZN) (HK: 8058) (KSE: 000100) (NSDQ: SRNE) (KOSDAQ: CHA) (NSDQ: LGND) (NSDQ: OSN) (KOSDAQ: 084990) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.